Patient communities are key partners in communications for pharmaceutical companies. But what does an impactful partnership look like? The Patient Partnerships Index aims to establish this.

Now, more than ever, we’re in need of cooperation – a shared perspective on how we can do things differently. We need to bring together the two forces operating at scale right now to support patients in the recovery from the COVID-19 pandemic.

First, there are the patient groups, tirelessly working to provide their communities with information, support and funds to safely get them through this difficult time. Second are the pharmaceutical companies working at pace to develop new vaccines and treatments, seconding staff and lab facilities to the effort to ensure the UK’s exit strategy has a meaningful impact on lives. At the same time, they are securing continuity of supply and getting medicines to where they need to be.

Putting patients at the heart of what the life science sector does has never been more critical. The Index will enable both pharmaceutical companies and patient groups to thrive, not just survive – so patients can ultimately live happier, healthier lives.

Jenny Ousbey, MD, OVID Health

All of this inspirational activity could not provide a better impetus for the Patient Partnership Index. The Index is the culmination of thoughtful discussion and research, with a sole goal in mind: to improve patient outcomes through high quality patient-pharmaceutical partnerships in communications, advocacy and market access.

The concept of patient centricity is mainstream now in research and development, including in clinical trials and patient support programmes. But the Index looks beyond ‘centricity’ in R&D and into partnerships of equals for three reasons: one, because ‘centricity’ can be passive; two, it is traditionally tied to R&D; and three, because top quality communications between companies and patient groups is about collaborating as equals.


The 2022 Index results

The Index is pleased to announce the results for 2022 as follows:

Gold Standard

Galapagos Biotech

Gilead Sciences

Gilead Sciences Ltd UK and Ireland

Medicine Discovery Catapult (MDC)

Novo Nordisk

Roche

Sanofi

Silver Standard

Eli Lilly and Company

Gilead Sciences Ltd UK and Ireland

GSK

Janssen

LEO Pharma

Novo Nordisk

Pfizer

Vifor Pharma

Finalist Standard

Novo Nordisk

Pfizer

Takeda

Commenting on the results, chair of Judges Jenny Ousbey said: “I was delighted to see a record number of entries to this year’s Patient Partnership Index, which is testament to the fantastic partnerships being developed by pharma and patient groups. I was particularly struck by the number of outstanding submissions showcasing successful and enduring long-term relationships between pharmaceutical companies and patient groups. These partnerships will undoubtedly help improve patient outcomes, an objective at the heart of the PPI. On behalf of all the judges, I would like to congratulate all those who entered, in particular those who were awarded gold standard.”

“The work pharmaceutical companies do with patient groups can have a tremendous impact on the health and wellbeing of patients and on public health. Sharing and supporting best practice can ensure partnerships between pharma and patient groups are collaborative, transparent and lead to meaningful change.”

Elliot Dunster, Executive Director, Corporate Affairs & Devolved Nations, ABPI